MACS
Latest Information Update: 28 Jan 2022
At a glance
- Originator Callitas Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inborn urea cycle disorders
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for research development in Inborn-urea-cycle-disorders(In infants, In neonates) in USA
- 18 May 2021 Camargo Pharmaceutical Services has been acquired by Premier Research Group
- 15 Mar 2018 The US FDA requests additional scientific and manufacturing information to approve orphan drug designation and rare paediatric disease designation requests